Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy in a combination regimen used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback